Conditions: Carcinoma, Non Small Cell Lung
Keywords: non small cell lung cancer HDAC proteasome inhibitor
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 18
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the efficacy of vorinostat and bortezomib in the third line treatment of advanced NSCLC, as well as to assess toxicity (including neuropathy) and tolerability of this regimen.

Detailed description:
Current treatment for non-small cell lung cancer (NSCLC) remains inadequate. Vorinostat is a novel agent that inhibits the enzymatic activity of histone deacetylases (HDACs). Bortezomib is a small molecule proteasome inhibitor. Preclinical and clinical studies have shown the advantages of combining these two agents in the treatment of NSCLC

Arms:
arm 1: Vorinostat 400 mg + Bortezomib 1.3 mg/m2

Interventions: intervention 1: vorinostat intervention 2: bortezomib
Intervention descriptions: intervention 1: 400 mg by mouth once daily for days 1-14 of each 21 day cycle intervention 2: 1.3 mg/m2 IV on days 1, 4, 8, 11 of each 21 day cycle

Protocol document: